- More Asset-Buying Depends on Economy: BOE
- Stocks Sputter as Investors Seek Next Catalyst
- Winners and Losers in Obama's Corporate Tax Plan
- Santorum Takes Heavy Fire in Arizona Republican Debate
- Volcker Rule Threatens Recovery: Finance Ministers
- Next Bank of England Governor: The Race is On
- HP, Dell Watch Rising China Labor Costs for Apple
- China Internet Firm Qihoo Says Citron Allegations False
- Romney Proposes Slashing Top Tax Rate to 28 Percent
- Wandering Through Toy Land
- Dell Is Done, But Don't Discount HP: Analysts
- Comcast Deal Could Spell Trouble for Netflix: Analyst
- Reading the Tea Leaves in RIM Shake-Up
- Sam Adams Brewer Crafts Beer for the Granddaddy of All Marathons
- Stocks to Give Up for Lent
- You Want Retail Customers? Give Them Deals: Analysts
- NJ Governor Chris Christie to Warren Buffett: 'Just Write a Check and Shut Up'
- 7 Undervalued IPO Stocks That Could Rebound in 2012
MOST SHARED
- More Asset-Buying Depends on Economy: Bank of England
- RBS to Pay Out $627 Million in Bonuses Despite Loss
- Japan Manufacturing Mood Dips to Levels After Quake
- Household Debt, Not Politics, Worry for Australia: Economist
- Japan's Sumo Belly Flops to $50 Million Debt
- 7 Undervalued IPO Stocks That Could Rebound in 2012
- Credit Agricole Posts $4.1 Billion Fourth Quarter Loss
- Break-Up, Greece Cause Huge 2011 Dexia Loss
- What if Mitt Romney Had Been President in 2009?
- The Rise and Fall of a Multibillion-Dollar Ponzi Scheme
MOST POPULAR
HOT ON FACEBOOK
Invest in Pharmaceuticals, Luxury: Portfolio Manager
Text Size 
European pharmaceutical stocks are cheap, offer high dividend yields and current valuations provide a good opportunity for investors to enter the sectors, Ana Armstrong, managing partner and head of portfolio strategy at Armstrong Investment Managers told CNBC.
European pharmaceutical companies are traded at a 25 percent discount to the broader index based on forecast 2011 earnings.
This low rating reflects concerns about future revenues as companies stand to lose exclusivity on their blockbuster drugs, Armstrong said.
US healthcare reforms and European austerity measures were also weighing on pharmaceuticals.
“They are investing billions in the new research projects. However, earnings expectations are at a 25 percent discount for 2011 which means this massive drug pipeline is being priced at zero,” Armstrong said.
“We can’t ignore the fact that billions of dollars are being invested in further research projects and we can’t be so pessimistic to believe that all that research will not generate any result and any progress. They will also benefit from the ageing population,” she added.
Armstrong also recommended investing in the luxury goods sector and singled out LVHM, Tiffany [TIF Loading... ()] and Swatch as favorite stocks.
Demand for high-end European brand names was exceptionally strong in Asia and other emerging markets and she was confident that it would continue to grow robustly.
———————————————————————————————————————————————
Disclosure information was not available for Ana Armstrong or Armstrong Investment Managers.
- The economy is heating up but the Fed isn’t letting up. How do you play the fixed-income market?
- With its rich oil reserves and rampant corruption, Azerbaijan poses a dilemma for U.S. policy makers.
- Business owners should occasionally consider giving their work for free. Here are several reasons why.
- GOP Governor Chris Christie wants Warren Buffett to stop talking about higher taxes on the super-rich.
- There’s a shortage of hotel rooms in London for the Olympics, so many locals are renting out their opulent private homes.
- Boston Beer will be creating a special commemorative brew, the Samuel Adams Boston 26.2, to mark this year's Boston Marathon.
Data is a real-time snapshot *Data is delayed at least 15 minutes
